[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-brain-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-brain-metastasis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100601172","multimodal-large-model-driven-risk-and-prognosis-assessment-for-brain-metastases-in-lung-cancer-100601172",false,"NCT07107035","Multimodal Large Model-Driven Risk and Prognosis Assessment for Brain Metastases in Lung Cancer","Multimodal Large Model-Driven Risk and Prognosis Assessment for Brain Metastases in Lung Cancer: A Nationwide, Multicenter, Observational Study","Inclusion Criteria:\n\n* Age≥18 years old;\n* KPS score≥70;\n* Pathologically confirmed lung cancer;\n* Receiving guideline-concordant standard-of-care therapy, defined as: radical surgical resection for early- to mid-stage non-small cell lung cancer (NSCLC); stereotactic radiotherapy for early-stage NSCLC deemed medically inoperable; radical chemoradiotherapy for locally advanced NSCLC; or systemic therapy for advanced-stage NSCLC.\n* Complete systemic imaging before treatment initiation, including contrast-enhanced brain MRI and contrast-enhanced chest CT;\n* Informed consent of the patient.\n\nExclusion Criteria:\n\n* Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years);\n* Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance;\n* Physical examination findings, clinical laboratory abnormalities, or other uncontrolled medical conditions identified by the investigator as potentially interfering with study results interpretation or increasing the patient's risk of treatment complications\n* Pregnant or lactating women.","ALL","18 Years",{"count":19,"type":20},20000,"ESTIMATED","OBSERVATIONAL","The goal of this nationwide, multicenter observational study is to develop and externally validate multimodal large models that can (1) predict the risk of brain metastases and (2) estimate long-term prognosis in patients with non-small cell lung cancer (NSCLC).\n\nThe main questions it aims to answer are:\n\n* Can a multimodal large model that fuses imaging, pathology, genomic, and clinical data accurately identify NSCLC patients at high risk of developing brain metastases?\n* Can a multimodal large model reliably forecast intracranial progression-free survival, progression-free survival, and overall survival across diverse real-world treatment settings? (ie, patients receiving distinct treatment regimens, in different treatment lines and with or without intracranial local therapies).\n\nBecause this is an observational study, there are no investigational treatments; instead, researchers will compare outcomes among patients who receive standard-of-care therapies (surgery, radiotherapy, systemic therapy) to determine how well the model's predictions align with observed events.\n\nParticipants will:\n\n* Allow use of their routinely collected clinical information, imaging (chest CT, brain MRI), pathology slides, and molecular test results for model training and validation\n* Undergo standard-of-care follow-ups\n* Complete optional quality-of-life questionnaires during scheduled visits",[24,25],"AI (Artificial Intelligence)","NSCLC Brain Metastasis","NOT_YET_RECRUITING","2025-07-30",{"date":29,"type":30},"2025-08-06","ACTUAL",{"date":32,"type":20},"2025-09",{"date":34,"type":20},"2030-07",{"name":36,"class":37},"Fudan University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100571171","tumor-treating-fields-ttf-in-combination-with-stereotactic-radiosurgerysrs-for-brain-metastases-from-non-small-cell-lung-cancer-100571171","NCT06716775","Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.","Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer: a Randomized, Controlled, Open-label Study.","Inclusion Criteria:\n\n1. The age of the subject was between 18 and 75 years old (inclusive), regardless of gender;\n2. The predicted survival time was ≥3 months;\n3. Newly diagnosed with NSCLC brain metastasis;\n4. MRI imaging showed 1-10 unresectable brain metastases;\n5. Karnofsky performance status (KPS) score ≥70;\n6. Able to operate the TTF independently or with the help of a caregiver;\n7. Subjects of childbearing potential had to agree to use effective contraception for the duration of the trial;\n8. Voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n1. Positive driver genes;\n2. Recurrent brain metastasis of NSCLC;\n3. Suffering from severe cerebral edema;\n4. Leptomeningeal metastases;\n5. Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following:\n\n   1. platelet count \\\u003C 100×103\u002FμL;\n   2. absolute neutrophil count \\\u003C 1.5×103\u002FμL;\n\n   d. AST or ALT exceeding 2.5 times the upper limit of normal; c.Total bilirubin more than 1.5 times the upper limit of the normal range; d.Severe renal impairment (serum creatinine \\>1.7 mg\u002FdL, or \\>150 μmol\u002FL);\n6. There were infection, ulcer and unhealed wound in the skin where the electrode was applied；\n7. Patients allergic to conductive hydrogels or medical adhesives;\n8. Those who are pregnant or preparing to become pregnant or who are breastfeeding;\n9. Patients with poor compliance, as judged by the investigator, or other factors considered by the investigator to be not suitable for the study.","75 Years",{"count":47,"type":20},200,"INTERVENTIONAL",[50],"NA","This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the treatment of brain metastases from non-small cell lung cancer (NSCLC) .",[25],[54,55],"TTF","NSCLC brain metastasis","2024-12-02",{"date":58,"type":30},"2024-12-04",{"date":60,"type":20},"2024-12-20",{"date":62,"type":20},"2028-10-30",{"name":64,"class":65},"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","INDUSTRY"]